OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
OSUR59

OraSure Technologies Inc

Medical Equipment, Supplies & DistributionVerified

OraSure Technologies Inc exhibits a strong liquidity position, with $199.28 million in cash and equivalents and a current ratio of 6.58, indicating a robust ability to meet short-term obligations. The company's debt-to-equity ratio is effectively zero, as it holds only $163,000 in long-term debt against $340.83 million in total equity, suggesting a conservative capital structure. However, the company reported negative operating and free cash flows of -$49.02 million and -$60.32 million, respectively, which may signal operational inefficiencies or high capital expenditures. Profitability metrics for OraSure are underperforming relative to industry norms. The company recorded a net loss of $68.73 million and an operating loss of $71.97 million, resulting in a return on equity of -20.17% and a return on assets of -17.05%. These figures are significantly below the industry's median profitability metrics, indicating a need for operational improvements or cost restructuring to align with sector performance. OraSure's revenue is concentrated in a single business segment focused on rapid diagnostic tests and related products, with no disclosed geographic diversification in the provided data. This concentration may expose the company to higher risk if demand for its primary product line fluctuates or if regulatory changes impact its operations. The company's growth trajectory appears to be under pressure, with a net loss in the most recent reporting period and no clear indication of revenue growth in the outlook. Analysts have assigned a mean price target of $4.00, with a median and high target also at $4.00, and a mean recommendation of 2.00 (indicating a "Hold"). These signals suggest limited upside potential in the near term and a cautious investor sentiment. Risk factors for OraSure include its negative operating and free cash flows, which could limit its ability to fund operations or invest in growth without external financing. The company has not disclosed any immediate dilution risks, and its liquidity position remains strong, with no filing-based flags detected. However, the absence of positive cash flow generation may necessitate future capital raises, which could introduce dilution risk if not managed carefully. Recent events, as reflected in the financial snapshot, show a continuation of operational losses and negative cash flows. No specific filings or transcripts are cited in the provided data, but the financial results suggest a challenging operating environment for the company.

30-day price · OSUR+0.53 (+17.2%)
Low$2.88High$3.65Close$3.61As of22 May, 00:00 UTC
Profile
CompanyOraSure Technologies Inc
TickerOSUR.O
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. OraSure Technologies Inc develops and markets rapid diagnostic tests and related products for the detection of infectious diseases, primarily HIV, and provides point-of-care diagnostic solutions for healthcare professionals and consumers.

Classification. OraSure is classified in the Healthcare Services & Equipment sector under the Medical Equipment, Supplies & Distribution industry, with a confidence level of 0.92 based on verified market data.

OraSure Technologies Inc exhibits a strong liquidity position, with $199.28 million in cash and equivalents and a current ratio of 6.58, indicating a robust ability to meet short-term obligations. The company's debt-to-equity ratio is effectively zero, as it holds only $163,000 in long-term debt against $340.83 million in total equity, suggesting a conservative capital structure. However, the company reported negative operating and free cash flows of -$49.02 million and -$60.32 million, respectively, which may signal operational inefficiencies or high capital expenditures. Profitability metrics for OraSure are underperforming relative to industry norms. The company recorded a net loss of $68.73 million and an operating loss of $71.97 million, resulting in a return on equity of -20.17% and a return on assets of -17.05%. These figures are significantly below the industry's median profitability metrics, indicating a need for operational improvements or cost restructuring to align with sector performance. OraSure's revenue is concentrated in a single business segment focused on rapid diagnostic tests and related products, with no disclosed geographic diversification in the provided data. This concentration may expose the company to higher risk if demand for its primary product line fluctuates or if regulatory changes impact its operations. The company's growth trajectory appears to be under pressure, with a net loss in the most recent reporting period and no clear indication of revenue growth in the outlook. Analysts have assigned a mean price target of $4.00, with a median and high target also at $4.00, and a mean recommendation of 2.00 (indicating a "Hold"). These signals suggest limited upside potential in the near term and a cautious investor sentiment. Risk factors for OraSure include its negative operating and free cash flows, which could limit its ability to fund operations or invest in growth without external financing. The company has not disclosed any immediate dilution risks, and its liquidity position remains strong, with no filing-based flags detected. However, the absence of positive cash flow generation may necessitate future capital raises, which could introduce dilution risk if not managed carefully. Recent events, as reflected in the financial snapshot, show a continuation of operational losses and negative cash flows. No specific filings or transcripts are cited in the provided data, but the financial results suggest a challenging operating environment for the company.
Key takeaways
  • OraSure Technologies Inc has a strong liquidity position with $199.28 million in cash and equivalents and a current ratio of 6.58.
  • The company is experiencing significant operational losses, with a net loss of $68.73 million and an operating loss of $71.97 million.
  • OraSure's profitability metrics, including a return on equity of -20.17%, are well below industry medians.
  • The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification.
  • Analysts have assigned a mean price target of $4.00 and a "Hold" recommendation, indicating limited near-term upside potential.
  • OraSure's negative operating and free cash flows may necessitate future capital raises, which could introduce dilution risk.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$115.0M
Gross profit$48.6M
Operating income-$72.0M
Net income-$68.7M
R&D
SG&A
D&A
SBC
Operating cash flow-$49.0M
CapEx-$4.2M
Free cash flow-$60.3M
Total assets$403.2M
Total liabilities$62.3M
Total equity$340.8M
Cash & equivalents$199.3M
Long-term debt$163.0k
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$340.8M
Net cash$199.1M
Current ratio6.6
Debt/Equity0.0
ROA-17.1%
ROE-20.2%
Cash conversion71.0%
CapEx/Revenue-3.6%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricOSURActivity
Op margin-62.6%3.9% medp25 -31.3% · p75 14.4%bottom quartile
Net margin-59.8%2.4% medp25 -30.5% · p75 11.1%bottom quartile
Gross margin42.2%46.7% medp25 28.2% · p75 63.1%below median
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-3.6%-4.8% medp25 -11.6% · p75 -2.4%above median
Debt / equity0.0%17.9% medp25 2.7% · p75 52.2%bottom quartile
Observations
IR observations
Mean price target4.00 USD
Median price target4.00 USD
High price target4.00 USD
Low price target4.00 USD
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count0.00
Hold count1.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.85 USD
Last actual EPS-0.94 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-22 22:30 UTC#bcf2bd5d
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 21:32 UTCJob: f53c1a61